CLINICAL TRIALS PROFILE FOR IMG-7289

Clinical Trials for IMG-7289

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02842827 ↗	IMG-7289, With and Without ATRA, in Patients With Advanced Myeloid Malignancies	Completed	Imago BioSciences,Inc.	Phase 1	This is a Phase 1 open label study of the dose and duration of an orally administered LSD1 inhibitor, IMG-7289, in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Some participants may also receive all-trans retinoic acid (ATRA; also known as tretinoin and Vesanoid®) in combination with IMG-7289. This study investigates the following: - The safety and tolerability of IMG-7289, with and without ATRA - The pharmacodynamic effect of different IMG-7289 doses and treatment durations, as well as IMG-7289 administered in combination with ATRA - The pharmacokinetics of IMG-2789, with and without ATRA
NCT03136185 ↗	IMG-7289 in Patients With Myelofibrosis	Active, not recruiting	Imago BioSciences,Inc.	Phase 2	This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with myelofibrosis. This study investigates the following: - The safety and tolerability of IMG-7289 - The pharmacokinetics of IMG-7289 (performed in Phase 1/2a only) - The pharmacodynamic effect of IMG-7289
NCT04081220 ↗	Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2	Recruiting	Imago BioSciences,Inc.	Phase 2	This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
NCT04081220 ↗	Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2	Recruiting	The University of Texas Health Science Center at San Antonio	Phase 2	This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
NCT04254978 ↗	IMG-7289 in Patients With Essential Thrombocythemia	Recruiting	Imago BioSciences,Inc.	Phase 2	This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with essential thrombocythemia. This study investigates the following: - The safety and tolerability of IMG-7289 - The pharmacodynamic effect of IMG-7289
NCT04262141 ↗	IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)	Recruiting	Imago BioSciences,Inc.	Phase 2	The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.
NCT04262141 ↗	IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)	Recruiting	Terrence J Bradley, MD	Phase 2	The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.

Clinical Trial Conditions for IMG-7289

Condition Name

Condition Name for
Intervention	Trials
Essential Thrombocythemia	2
Thrombocythemia, Essential	2
Myelofibrosis	2
Polycythemia Vera	2

Condition MeSH

Condition MeSH for
Intervention	Trials
Thrombocytosis	5
Thrombocythemia, Essential	5
Primary Myelofibrosis	3
Polycythemia Vera	3

Clinical Trial Locations for IMG-7289

Trials by Country

Trials by Country for
Location	Trials
United States	6
Australia	3
United Kingdom	2
Hong Kong	2
Italy	2

Trials by US State

Trials by US State for
Location	Trials
Florida	2
Ohio	1
Texas	1
Michigan	1
Washington	1

Clinical Trial Progress for IMG-7289

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	7
Phase 1/Phase 2	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Recruiting	5
Not yet recruiting	3
Active, not recruiting	1

Clinical Trial Sponsors for IMG-7289

Sponsor Name

Sponsor Name for
Sponsor	Trials
Imago BioSciences,Inc.	10
Terrence J Bradley, MD	2
The University of Texas Health Science Center at San Antonio	1

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	10
Other	5
NIH	1